PDGFRB and hematopoietic and lymphoid system neoplasm: After the detection of PDGFRB rearrangement, imatinib was given at a dose of 400 mg/day, since previous studies have reported a positive outcome from this dose in patients with hematologic neoplasms with PDGFRB rearrangement (Cheah et al., 2014; Jawhar et al., 2017).